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The small heat shock protein HSPB1 (Hsp27) is an ubiquitously expressed molecular chaperone able to regulate
various cellular functions like actin dynamics, oxidative stress regulation and anti-apoptosis. So far disease causing
mutations in HSPB1 have been associated with neurodegenerative diseases such as distal hereditary motor
neuropathy, Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis. Most mutations in HSPB1 target its
highly conserved α-crystallin domain, while other mutations affect the C- or N-terminal regions or its promotor.
Mutations inside the α-crystallin domain have been shown to enhance the chaperone activity of HSPB1 and
increase the binding to client proteins. However, the HSPB1-P182L mutation, located outside and downstream of
the α-crystallin domain, behaves differently. This specific HSPB1 mutation results in a severe neuropathy phenotype
affecting exclusively the motor neurons of the peripheral nervous system. We identified that the HSPB1-P182L
mutant protein has a specifically increased interaction with the RNA binding protein poly(C)binding protein 1
(PCBP1) and results in a reduction of its translational repressive activity. RNA immunoprecipitation followed by RNA
sequencing on mouse brain lead to the identification of PCBP1 mRNA targets. These targets contain larger 3′- and
5′-UTRs than average and are enriched in an RNA motif consisting of the CTCCTCCTCCTCC consensus sequence.
Interestingly, next to the clear presence of neuronal transcripts among the identified PCBP1 targets we identified
known genes associated with hereditary peripheral neuropathies and hereditary spastic paraplegias. We therefore
conclude that HSPB1 can mediate translational repression through interaction with an RNA binding protein further
supporting its role in neurodegenerative disease.
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HSPB1 (Hsp27) is a member of the small heat shock
protein family (sHSPs), comprising ubiquitously expressed
molecular chaperones whose canonical function is to pre-
serve cellular proteostasis during stress conditions. In con-
trast to heat shock proteins with an ATPase domain (e.g.,
HSP70), sHSPs do not have the intrinsic capacity to refold
denatured proteins. However, they are able to bind to un-
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heat shock proteins [17]. Besides this canonical function,
HSPB1 is also known to regulate actin dynamics, cell
differentiation and to have anti-apoptotic and anti-
oxidant functions [5]. HSPB1 is characterized by a highly
conserved α-crystallin domain, which is found essential
for its biological function and dimer formation [17].
So far, 26 mutations (including 22 missense mutations)
have been found in HSPB1 that are responsible for
axonal Charcot-Marie-Tooth neuropathy (CMT2F), distal
hereditary motor neuropathy (dHMN) and amyothropic
lateral sclerosis (ALS) [7, 11, 14, 27, 49]. Depending on
where the mutations are located in the HSPB1 gene,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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function and patient’s clinical outcome. The vast majority
of mutations found in HSPB1 are linked with CMT2F/
dHMN type II and reside in the well-conserved α-
crystallin domain [37]. The CMT2F patients typically
present with mixed sensory and motor symptoms, while
motor neurons are predominantly affected in patients
with dHMN type II [24]. It is surprising that mutations
in this ubiquitously expressed molecular chaperone spe-
cifically affect the peripheral nerves suggesting a key role
in the highly polarized motor and sensory neurons.
In this work we specifically focus on the P182L muta-
tion in HSPB1 which was first reported in 2004 in a sib-
ling of an Austrian dHMN family [14]. The onset of the
disease phenotype was at the age of 5 and although the
last examination was at the age of 16, there was already
the presence of gait difficulties and weakness of the dis-
tal upper and lower limbs associated with muscular atro-
phy. The formation of pes cavus and the manifestation
of brisk knee reflexes were also reported [11]. Interest-
ingly, when studying the functional consequences of this
particular HSPB1 mutation, the severity of the P182L
mutation was further supported by an increased pres-
ence of aggregates in cell lines upon overexpression of
the mutant protein [1]. In addition, and similar to the
other studied HSPB1 mutations, the P182L mutation
causes an increase in the phosphorylation of neurofila-
ments and disturbances in the axonal transport [20].
Whereas the CMT2F causing HSPB1 mutations in the
α-crystallin domain of the protein show an increased
binding to their client proteins leading to an overstabili-
zation of microtubules, the P182L mutation does not
cause this aberration and behaves as the wild-type
HSPB1 protein [3, 4]. Overall, this indicates that the in-
creased clinical severity of the P182L mutation is caused
by additional, unidentified factors.
In order to characterize HSPB1 mutations we previously
performed interaction studies by using tandem affinity
purification coupled to mass spectrometry (TAP-MS) [4].
This study revealed an RNA binding protein named poly(-
C)binding protein1 (PCBP1) as an unreported and novel
interaction partner for the wild type and P182L mutant
HSPB1. Here, we studied the interaction between PCBP1
and wild type HSPB1 through in vitro experiments and
found the interaction to be increased for HSPB1-P182L,
both in a dHMN patient derived lymphoblastoid cell line
and in HeLa cells transiently expressing wild type and
mutant HSPB1. Interestingly, this increased interaction
resulted in a loss of translational repression of PCBP1 on
its mRNA targets. By using RNA immunoprecipitation
followed by RNA sequencing we identified the targets
that specifically bind to PCBP1. Of note, there are nine
genes among these targets that when mutated are
known causes for inherited peripheral neuropathies(IPN) and hereditary spastic paraplegia (HSP) (Inf2,
Sox10, Wnk1, Med25, Fa2h, Bscl2, Slc12a6, Kif1a and
Kif5a) [13, 21, 29, 31, 40–42, 52].
Materials and methods
Clinical phenotype of dHMN patients with the
HSPB1-P182L mutation
The first reported patient in 2004 carrying an HSPB1-
P182L mutation (c.545C > T), patient CMT-391:II.I,
belonged to an Austrian family where also a younger sib-
ling was affected. A disease phenotype was reported at
the age of 5 and until the last examination at the age of
16, the patient showed gait difficulties, weakness of the
distal upper and lower limbs associated with muscular
atrophy. In addition, pes cavus and brisk knee reflexes
were reported. None of the asymptomatic parents
showed the heterozygous HSPB1-P182L mutation but a
parental mosaicism for the mutation was identified [11].
This patient was clinically diagnosed by M.A.G.
Creation of constructs and stable cell lines
Constructs used for transient transfection experiments
and to generate stable SH-SY5Y cell lines were designed
using the Gateway recombination system (Life Tech-
nologies). The open reading frames (ORF) of HSPB1
(NM_001540), PCBP1 (NM_006196) and EGFP were
amplified by PCR using specific primers flanked by attB
recombination sites to allow the insertion of the product
in the pDONR221 vector. The described HSPB1 muta-
tions (HSPB1-R127W and HSPB1-P182L) were generated
by site-directed mutagenesis. Sequence validated pDONRs
were transferred by recombination to the pLenti6/V5 des-
tination vector (Life Technologies) allowing us to generate
constructs where the ORF is fused to a V5-tag. To gen-
erate the PCBP1-VSV construct, the pDONR was trans-
ferred by recombination to a pCR3/VSV destination
vector. For the luciferase assays we cloned the PCBP1
and EGFP cDNA’s upstream of a MS2 binding protein
ORF containing plasmid [50]. All the final plasmids
were verified by Sanger sequencing.
Stable cell lines were generated by lentiviral trans-
duction of the neuronal cell line SH-SY5Y, according to
the method described previously [43]. Stable cell lines
presented similar expression levels and equal growth
rate (data not shown).
Cell culture material and conditions
All cell culture media and supplements were purchased
from Life Technologies. The human neuroblastoma cell
line SH-SY5Y was purchased from ATCC and cultivated
at 37 °C and 5% CO2 in EMEM supplemented with 10%
fetal calf serum (FCS), non-essential amino acids, Glu-
tamine and Penicillin-Streptomycin. The HeLa cell line
was purchased from ATCC and cultivated at 37 °C and
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tamine and Penicillin-Streptomycin. The HEK293 cell
line was purchased from ATCC and cultivated at 37 °C
and 5% CO2 in DMEM supplemented with 10% FCS,
HEPES, Glutamine and Penicillin-Streptomycin. The
NSC-34 cell line was purchased from ATCC and culti-
vated at 37 °C and 5% CO2 in DMEM supplemented
with 10% FCS, HEPES, Glutamine and Penicillin-
Streptomycin. From the patients we obtained lympho-
cytes through venipuncture and lymphoblastoid cell
lines were EBV-transformed and cultivated at 37 °C and
6% CO2 in Gibco® RPMI 1640 supplemented with 15%
FCS, Sodium Pyruvate and Penicillin-Streptomycin. Be-
sides the described HSPB1-P182L patient we also obtained
lymphocytes from an HSPB1-R127W patient (cmt751.01)
and a healthy control individual (ceph1454.14). Fibroblasts
were obtained from patients by taking skin biopsies and
cultivated at 37 °C and 6% CO2 in DMEM/F12 supple-
mented with 10% FCS, Sodium Pyruvate and Penicillin-
Streptomycin. We obtained approval from our local
medical ethical committees to perform this study.
Transient transfection
HeLa cell lines were transfected by using Lipofectamine
LTX transfection reagent (Life Technologies) according
to the manufacturer’s protocol. Briefly, cells were seeded
out in 10 cm dishes at 1.5 × 106 cells per dish 24 h be-
fore transfection. On the day of transfection, media was
renewed without the addition of antibiotics. Transfection
was performed using 4000 ng plasmid DNA supplemented
with 20 μl Lipofectamine LTX transfection reagent. Cells
were lysed and assessed by co-immunoprecipitation, 24 h
post transfection.
HEK293 cell lines were transfected by using polyethy-
lenimine (PEI) according to an in house optimized
protocol. Briefly, cells were seeded out in a 24 well plate
at 7x104 cells per well, 24 h before transfection. On the
day of transfection, media was renewed without the
addition of antibiotics and containing a reduced serum
concentration (2%). 500 ng plasmid DNA was diluted in
36 μl Opti-MEM (Life-Technologies) and in parallel,
2.5 μl PEI was diluted in 36 μl Opti-MEM. The diluted
PEI was added to the DNA and mixed by gently vortex-
ing. After 15 min of incubation at room temperature,
the solution was added to the cells.
Western blotting
Cells were lysed in lysis buffer (0.5% Nonidet P-40,
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4, 4 mM Sodium orthovanadate, 20 mM Glycerol-
2-Phosphate, 10 mM Sodium Fluoride, 1 mM Sodium
Pyrophosphate, together with complete protease and
Phospho-STOP inhibitor mixtures - Roche Applied Sci-
ence) for 30 min on ice and cleared by centrifugationfor 10 min at 14,000 rpm. After protein concentration
was determined, by using the Bradford protein assay
(Bio-Rad), cell lysates were boiled for 5 min at 95 °C in
reducing Laemmli buffer (Life Technologies) supple-
mented with 100 mM 1.4-Dithiothreitol (DTT). Proteins
were separated on NuPAGE gels (Life Technologies) and
transferred to a nitro-cellulose-membrane (Hybond™-P,
GE Healthcare). Blocking of the membrane was per-
formed using 5% milk powder diluted in PBS, supple-
mented with 0.1% Tween 20. Afterwards, membranes
were incubated with a primary antibody over night at 4 °C
and one hour with a secondary horseradish peroxidase
conjugated antibody. Blots were developed by using the
Enhanced Chemiluminescence ECL Plus™ detection sys-
tem (Thermoscientific) and imaged with an ImageQuant
imager (GE Healthcare). The following antibodies were
used: anti-HSPB1 (Enzo Life Sciences), anti-V5 (Life Tech-
nologies), anti-VSV (Sigma-Aldrich) and anti-PCBP1
(Santa Cruz Biotechnology and Novus Biologicals).
Band intensities were determined by quantifying the
mean pixel grey values using the ImageJ software [44].
Mean pixel grey values were measured in a rectangular
region of interest.
Co-immunoprecipitation
Cells were lysed in lysis buffer (0.5% Nonidet P-40,
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4, 4 mM Sodium orthovanadate, 20 mM Glycerol-
2-Phosphate, 10 mM Sodium Fluoride, 1 mM Sodium
Pyrophosphate, together with complete protease and
Phospho-STOP inhibitor mixtures - Roche Applied Sci-
ence) for 30 min on ice and cleared by centrifugation for
10 min at 14,000 rpm. Protein concentration was deter-
mined, by using the Bradford protein assay (Bio-Rad), in
order to equalize the protein concentration from different
cell lines. Sepharose 6B (Sigma-Aldrich) and protein G
beads (GE Healthcare) or anti-V5 beads (Sigma-Aldrich)
were used in a 3:1 ratio. Cell lysates with an equal protein
concentration were incubated together with the bead mix-
ture and the desired antibody, when needed, and left on a
rotating device overnight at 4 °C. Afterwards the beads
were collected by centrifugation and washed repeatedly
with the same buffer as used for lysis of the cells. After the
last washing step beads were resuspended in reducing
Laemmli buffer (Life Technologies) supplemented with
100 mM DTT and boiled for 5 min at 95 °C prior to be
loaded on NuPAGE gels (Life Technologies).
Polysome Gradient Analysis
Polysomal and non-polysomal fractions were separated
according to a standardized protocol. Briefly, cells were
collected by centrifugation, lysed in lysis buffer (30 mM
Tris-HCl; pH7.4, 100 mM NaCl, 10 mM MgCl2 and
0.1% Triton X-100) and clarified by centrifugation for
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onto a 5–50% sucrose gradient (30 mM Tris-HCl;
pH7.4, 100 mM NaCl, 10 mM MgCl2 and 5–50% su-
crose) and centrifuged at 37,000 rpm for 3.5 h at 4 °C in
a Beckman-Coulter LE-80 K. Fractions of each gradient
were collected by monitoring at 260 nm and precipitated
with 50% ethanol, 25% methanol and 25% acetone. After
precipitation, pellets were washed in 0.3 M Guanidinium-
HCl in 96% ethanol. The purified pellet was dissolved in
Laemmli buffer (Life Technologies) supplemented with
100 mM DTT and boiled for 5 min at 95 °C prior to be
loaded on NuPAGE gels (Life Technologies).
Luciferase assay
HEK293 cells were co-transfected with a luciferase re-
porter, PCBP1 or EGFP and HSPB1 wild type or mutants
by using PEI as described before. Luciferase activity was
measured with the Dual-luciferase reporter assay system
(Promega) and following the manufacturer’s protocol.
The luciferase activity was normalized by the renilla
activity in order to correct for inter-well variations.
Immunocytochemistry and immunofluorescence microscopy
Immunostainings were performed according to a stan-
dardized protocol. Briefly, cells were seeded out on glass
coverslips the day before fixation. Fixation was per-
formed by incubating the cells with 4% paraformalde-
hyde for 20 min. Afterwards cells were permeabilized
with 0.1% Triton X-100 in phosphate buffered saline
(PBS). Blocking was performed with 5% BSA diluted in
PBS for 1 h, primary and secondary antibodies were in-
cubated for 1 h diluted in 1% BSA in PBS supplemented
with 0.1% Tween 20. The following antibodies were
used; anti-HSPB1 (Enzo Life Sciences), anti-V5 (Life
Technologies), anti-NFH (Covance), anti-PCBP1 (Santa
Cruz Biotechnology), anti-mouse IgG Alexa Fluor 488
(Life Technologies), anti-goat IgG Alexa Fluor 488 (Life
Technologies), anti-mouse IgG Alexa Fluor 594 (Life
Technologies) and anti-goat IgG Alexa Fluor 594 (Life
Technologies). Nuclear staining was performed with
DAPI (Life Technologies), afterwards cells were mounted
with fluorescent mounting medium (Dako). Images were
taken on a LSM700 confocal fluorescence microscope
using a 63×/1.40 plan-apochromatic objective. Possible
cross-talk of the fluorescence channels was excluded by
employing frame-by-frame scanning.
Neurite outgrowth of neuroblastoma cells
The human neuroblastoma cell line SH-SY5Y stably
expressing different HSPB1 constructs was cultured in
the presence of 20 μM retinoic acid (Sigma Aldrich) to
induce neuronal differentiation after seeding. Phase con-
trast images were acquired with a Carl Zeiss Axiovert
200 M using a 10× objective (Plan NeoFluar Ph1 0.3NA) and Zeiss AxioCamMR3 camera. Images were ac-
quired of the same microscopic fields of cells on con-
secutive days, making use of the automated positioning
function of the motorized microscope stage. To deter-
mine neurite outgrowth, a specific image analysis pro-
cedure was developed in ImageJ [44] to extract from
each image the neuritic structures from the background
and cell bodies. The pipeline consists of a combination
of noise reduction filters, bandpass filtering in the
Fourier space, local and global intensity thresholding,
and combining resulting masks of different segmentation
algorithms with Boolean operations. The final neurite
mask was derived after a skeletonization step and its
total size was used as a measure for the neurite length.
The analysis was run in batch on all images using an
ImageJ macro script.
RNA isolation from mouse tissues
To measure the abundance of mRNA in various mouse
tissues, RNA isolation was performed. Animals were
euthanized by CO2 inhalation and the brain, heart, liver,
lung, muscle, sciatic nerve and spinal cord were
dissected out and snap frozen in liquid nitrogen. The
frozen tissues were homogenized in Trizol (Qiagen) and
total RNA was isolated by using the RNeasy Lipid Tissue
Mini kit (Qiagen) according to manufacturer’s protocol.
All mouse experiments were approved by the Ethical
Committee for Laboratory Animals (University of
Antwerp). The mice were housed and maintained at the
Animal Facility Interfaculty Unit, which is accredited by
the Association for Assessment and Accreditation of
Laboratory Animals.
RNA-immunoprecipitation (RNA-IP)
Total mouse brain was lysed in lysis buffer (50 mM
Tris-HCl; pH 7.4, 150 mM NaCl, 0.1% Triton X-100,
1 mM DTT together with complete protease inhibitor
mixture - Roche Applied Science), put on ice for 30 min
and cleared by centrifugation for 10 min at 14,000 rpm.
40 Units/ml RNase OUT (Life Technologies) was added
to the cleared lysate. After determining the protein
concentration by using the Bradford protein assay (Bio-
Rad), the lysate was diluted to a final concentration of
1 mg/ml in immunoprecipitation buffer (50 mM Tris-
HCl; pH 7.4, 200 mM NaCl, 0.1% Triton X-100 and
2 mg/ml Heparin) and prepared for preclearing. Pre-
clearing was performed on the diluted lysate by adding
50 μl Dynabeads (Life Technologies) without the presence
of an antibody. After leaving the beads on a rotating
device for 60 min at 4 °C, supernatant was taken for
immunoprecipitation by adding 50 μl Dynabeads sup-
plemented with 7 μg PCBP1 antibody (Santa Cruz Bio-
technology). In parallel, a negative control was created
by using 50 μl Dynabeads and 7 μg normal goat IgG
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ground mRNAs binding to the Dynabeads. As for the
preclearing, the samples for immunoprecipitation were
left on a rotating device for 60 min at 4 °C. Afterwards
beads were washed four times with washing buffer
(50 mM Tris-HCl; pH 7.4, 200 mM NaCl, 0.1% Triton
X-100 and 1 mM MgCl2). After the final wash beads
were resuspended in elution buffer (200 mM NaOAc,
1 mM EDTA and 0.5% SDS) and heated up to 75 °C for
5 min. RNA was isolated on this fraction by phenol/
chloroform extraction.
RNA sequencing
Purified RNA originating from the RNA-IP was sequenced
on an Illumina HiSeq platform by paired-end sequencing.
Library prepping was performed by using the TruSeq
RNA Library Prep Kit from Illumina. The sequencing data
were mapped to the mouse mm10 reference genome
(Release date: December 2011) and thoroughly analyzed.
Differential gene expression analysis was performed with
the DESeq algorithm (Bioconductor 2.13).
RT-qPCR
Isolated RNA was assessed on concentration and purity
by Nanodrop (Thermoscientific) measurement. DNase
treatment was performed by using the TURBO™ DNAse
treatment kit (Life Technologies) and cDNA conversion
was performed by using the M-MLV Reverse Tran-
scriptase system (Life Technologies) according to man-
ufacturer’s protocol. To determine the amount of a
transcript being present in the RNA-IP, relative expres-
sion levels were determined by qPCR experiments. The
reactions were performed using Power SYBR® Master
Mix (Life Technologies) according to manufacturer’s
instructions and run on a ViiA 7 Real-Time PCR system
(Applied Biosystems). All the reactions were preformed
in triplicate and normalized to IgG as negative control.
Primers were designed making use of Primerbank
(http://pga.mgh.harvard.edu/primerbank). Primers were
validated for specificity and amplification efficiency.
Calculation motif frequencies
Biomart and Perl API from Ensembl was used to extract
the genomic coordinates and the sequences for the
exons, 5′UTRs, 3′UTRs and introns belonging to the
coding transcripts in mouse database v82. Only the tran-
scripts having complete annotation and sequences avail-
able for all 4 features: exons, 5′UTR, 3′UTR and introns
were used. The motif frequency was calculated in each
of the 4 features of each transcript using the count of
the exact match for the motif CTCCTCCTCCTCC (and
reverse complement; GAGGAGGAGGAGG) in the fea-
ture and normalized to the transcript length.Statistical analysis
For all experiments, results are shown as average with
standard deviation. GraphPad Prism software was used
for all statistical analysis. One way ANOVA with Holm-
Sidak multiple comparison Test was used to analyze the
quantification of the ratio PCBP1/HSPB1 in transiently
transfected HeLa cell lines. To analyze the median 3′-
and 5′-UTR length of the top 50 PCBP1-regulated tar-
gets a One Sample Wilcoxon signed-rank test was per-
formed. Multiple t-test with Holm-Sidak as a correction
for multiple comparisons was performed as statistical
test for the qPCR validation graphs. The p-values were
calculated on at least three independent experiments. A
two-sample one-sided Kolmogorov-Smirnov test in R
package was performed to test statistical significance in
the motif frequencies analyzed in 3′-UTR, 5′-UTR, in-
trons and exons of enriched target genes.
Results
Mutant HSPB1 shows an increased affinity for PCBP1, a
novel binding partner
In order to address how mutations in HSPB1 may cause
CMT neuropathy, we previously performed a tandem af-
finity purification on HEK293 cells stably expressing
HSPB1 wild type and different CMT causing mutations
[4]. Mass spectrometry analysis resulted in the identifi-
cation of the poly(C)binding protein 1 (PCBP1) as an
interacting protein for wild type HSPB1 showing an
increased affinity for mutant HSPB1. PCBP1 has been
catalogued as an RNA binding protein and alternatively
named as heterogeneous nuclear protein E1 (hnRNP
E1). Together with HSPB1, PCBP1 is ubiquitously
expressed and present in mouse peripheral nervous
tissues (Additional file 1: Figure S1).
To further investigate this novel HSPB1 interaction part-
ner, immunoprecipitation (IP) was performed by the pull
down of endogenous PCBP1 in patient-derived lympho-
blastoid cell lines. Interestingly, a co-immunoprecipitation
of the HSPB1-P182L mutant (in the C-terminal domain)
and not for the HSPB1-R127W mutant (in the α-crystallin
domain) and HSPB1 wild type (WT) was observed
(Fig. 1a). This was further confirmed by the pull-down of
HSPB1/EGFP, fused to a V5-tag in HeLa cell lines, transi-
ently expressing HSPB1-WT, HSPB1-R127W, HSPB1-
P182L and EGFP (a negative control). The HSPB1-R127W
was chosen as an additional control for HSPB1-P182L, as
this α-crystallin domain mutant is biological different and
shows an increased chaperone activity and binding to
client proteins, like tubulin, while HSPB1-P182L does not
[2]. Interestingly, in HeLa cells the P182L mutant was
more present in a complex with PCBP1, compared to
HSPB1 wild type and HSPB1-R127W (Fig. 1b). These
observations were further confirmed by western blot
quantification (Fig. 1c). It still remains to be determined
Fig. 1 Identification of PCBP1 as a novel interaction partner of wild type and mutant HSPB1. a Co-immunoprecipitation was performed on
patient-derived lymphoblastoid cell lines. Pull-down was directed against endogenously expressed PCBP1 and checked for the presence of
endogenous HSPB1. IgG was used as a negative control. b Co-immunoprecipitation was performed on transiently transfected HeLa cell lines,
clearly showing the binding of PCBP1 to HSPB1-WT and the increased binding to HSPB1-P182L. Pull down was directed against the V5-tag of
the HSPB1 constructs and the presence of PCBP1 was checked with a VSV-tag. EGFP-V5 was used as a negative control. c Calculation of the
PCBP1/HSPB1 ratio after quantification of the relative band intensities (n = 3). A One way ANOVA with Holm-Sidak multiple comparison test was
performed to indicate the significant increased interaction of HSPB1-P182L with PCBP1. Data are represented as mean values with SD as error bars
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direct or indirect.
When looking for co-expression of HSPB1 and PCBP1
in vivo, we found a stronger abundance of PCBP1 and
HSPB1 during mouse embryonic development (Additional
file 1: Figure S2), which further suggest that the inter-
action between these two proteins is taking place at spe-
cific moments in the cell, for example during the need
for protein translation. Given the increased interaction
of PCBP1 with the HSPB1-P182L mutant, we evaluated
the effect of the P182L mutation on PCBP1 cellular
localization, which is mostly present in the nucleus but
also noticeable expressed in the cytosol. The PCBP1
localization is similar in fibroblasts of patients carrying
the P182L mutation compared to control fibroblasts,
without any apparent effect of the P182L mutation on
the localization of HSPB1 and PCBP1 (Additional file 1:
Figure S3). In addition, we assessed the expression of
PCBP1 in differentiated neuroblastoma cell lines ex-
pressing either wild type or mutant HSPB1 (P182L or
R127W). No differences were found in PCBP1
localization, nor had the mutations an effect on neurite
outgrowth (Additional file 1: Figure S4). Notably, theformation of large protein aggregates, typically seen for
C-terminal mutations in HSPB1 [1, 9], could not be
detected in fibroblasts originating from the patient
(HSPB1-P182L) or control individual, nor in the neuro-
blastoma cell lines stably expressing levels of the HSPB1
constructs that were comparable with the endogenous
protein. We hypothesize that, because of its nature, this
C-terminal mutation is more prone to from larger oligo-
meric complexes by the substitution of a polar with a
hydrophobic amino acid. This makes it less solvent
soluble and increases its interacting properties with
other small heat shock proteins or other binding pro-
teins. Depending on the cellular expression system used,
the cell type and the presence of cellular stress, this
mutation can lead more easily to protein aggregation.
Mutant HSPB1 influences the biological activity of PCBP1
RNA binding proteins play a crucial role in the regulation
of expression of many genes. One of the best-known
functions of PCBP1 is its ability to repress translation
by preventing the ribosomal units to dock and assemble
on mRNA [16]. Therefore we investigated the effect of
this increased interaction on total mRNA translation.
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trifugation of patient-derived lymphoblastoid cells, the
polysomes, monosomes, ribosomal subunits and ribo-
nucleoproteins. A more active translation status of
mRNAs would result in a more profound presence of
ribosomes, and the Rps6 ribosomal marker, in the poly-
somal fractions. We saw no differences in total protein
translation between the different genotypes when com-
paring mutant (HSPB1-R127W and HSPB1-P182L) to a
healthy control individual (Fig. 2a). After loading the
different isolated polysome fractions on gel, no differ-
ences in the distribution of PCBP1 could be demon-
strated (Fig. 2b-d). PCBP1 was mostly present in the
top fractions indicating that the protein is a monomer
or part of small complexes, a pattern that was already
reported before for PCBP1 [39] and other hnRNPs [25].
Interestingly, HSPB1-P182L shows a shift towards the
heavier fractions containing the 40S ribosomal subunit,
which might be explained by the nature of the mutation
favoring complexes of larger oligomeric structures [9].
To test for specific alterations in the activity of PCBP1,
we performed a luciferase-based repression assay in
HEK293 cells where mRNA recognition sequences for a
PCBP1-MS2 fusion protein are cloned in the 3′UTR of
the luciferase reporter gene. This approach enables us to
study the effect of PCBP1 on the translation of the lucif-
erase protein with or without the addition of wild type
and mutant HSPB1. The expression of PCBP1 resulted
in a severe reduction of the luciferase signal by approxi-
mately 68% when compared to an EGFP negative control
(Fig. 3a). The conditions with and without HSPB1-WT
or HSPB1-R127W, revealed no differences in the activityFig. 2 HSPB1 mutants do not show differences in general protein translation
gradient with protein lysates originating from patient- and control-derived ly
polysome gradient analysis were assessed by western blotting. Rps6 was use
control individual (b) is due to technical variationof PCBP1. Interestingly, a small but consistent loss in
the activity of PCBP1 was observed when HSPB1-P182L
was present (Fig. 3a). When comparing the luciferase
values normalized to HSPB1-WT, it becomes clear that
the control mutant HSPB1-R127W does not have an ef-
fect on the activity of PCBP1 (99,97 ± 5,09), but that
HSPB1-P182L does and reduces the activity by approxi-
mately 20% (118,54 ± 2,97; Fig. 3b).
Identification of PCBP1 target mRNAs from mouse brain
To try to understand the effect of HSPB1-P182L on the
mRNA targets regulated by PCBP1, we aimed to identify
its binding transcripts. For that, we immunoprecipitated
PCBP1 from adult mouse brain and isolated the bound
mRNA. Total mouse brain was used instead of sciatic
nerve or spinal cord because of too low starting material
in the latter two tissues. In three independent experi-
ments, total RNA was isolated from the IP and analyzed
by RNA sequencing (RIP sequencing). Pre-immune serum
coupled beads (IgG) was used as a negative control to ac-
count for the background mRNAs (Fig. 4a). To validate
our results we confirmed by RT-qPCR the expression pro-
files of the top 10 and bottom 10 genes, present in the 4th
quartile of the list containing transcripts identified by RIP
sequencing (Fig. 4b-c). The correlation between RT-qPCR
and RNA sequencing data for 50 additional genes
(Additional file 2: Table S1) was highly significant (Pear-
son’s correlation coefficient = 0,641; Fig. 4d), indicating
that the RNA sequencing data are robust and reliable. The
identified mRNAs were ranked by enrichment in the IP
relative to input and normalized to the negative control
IgG (Additional file 3: Table S2). This allowed us to. a The polysome gradient analysis was performed on a 5-50% sucrose
mphoblastoid cell lines. b-d The isolated fractions originating from the
d as a ribosomal marker. The HSPB1 band visible in fraction 1 of the
Fig. 3 HSPB1-P182L reduces the translational repression activity of PCBP1. a Luciferase-based repression assay performed on HEK293 cell lines
transiently transfected with PCBP1/EGFP alone or with PCBP1 together with wild type or mutant HSPB1. All data were subsequently normalized
to the renilla luciferase and EGFP, which was used in this assay as a negative control. b Values from the same luciferase-based repression assay
normalized to HSPB1-WT. All experiments were performed four times. Statistical analysis was performed by one way ANOVA with a Bonferroni
multiple comparison test
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the PCBP1 IP (using an average of ≥ 2-fold enrichment
as a cutoff across three IPs and an adjusted p-value ≤
0,05; Fig. 4e). This set represented approximately 7,4% of
mRNAs expressed in the input fractions.
Although RBPs are forming dynamic protein com-
plexes, increasing evidence demonstrate that individual
RBPs can regulate a biologically coherent set of target
mRNAs in order to coordinate their expression profiles
[19, 26]. We therefore performed DAVID Gene Ontology
(GO) term analysis on the targets of PCBP1 identified
by RIP sequencing (≥2-fold). A significant enrichment
of several GO term categories was found, including
transcription and regulation of transcription (p-values
of 1,64 × 10−18 and 1,01 × 10−17, respectively; Fig. 4f ).
Interestingly, several GO term categories were associated
with neuronal processes like neuromuscular process, syn-
apse organization and neurogenesis. RT-qPCR analysis
confirmed the genes belonging to these selected GO term
categories as being significant PCBP1 targets. Interest-
ingly, there was a strong association of Shank1 and
Shank3 (p ≤ 0,0001 and p ≤ 0,01 respectively) with PCBP1
(Additional file 1: Figure S5). These proteins are present
in the synapse and crucial in making the connection
between the actin cytoskeleton and neurotransmitter re-
ceptors [33]. In addition, Shank1 null mutant mice display
reduced motor coordination and neuromuscular strength
[46]. Taking together there is a strong indication that
PCBP1 plays a role in regulating the expression profile of
several genes in the synapses of neuronal cells.
PCBP1 mRNA targets have larger UTRs and share a
common recognition sequence
In order to investigate how PCBP1 might regulate spe-
cific transcripts in the neuron, we searched for structural
elements enriched in PCBP1 mRNA targets. RNAbinding proteins have a preference to bind to the 5′-
and 3′-UTR of transcripts. Depending on the UTR
where it binds, it can have multiple different functions
[10]. Here, we took advantage of our three independent
RNA sequencing experiments to select the most strin-
gent set of targets. We selected those mRNAs that were
highly enriched in the PCBP1 IP but in addition we se-
lected as well the targets that were less enriched. This
resulted in 103 targets that were subjected to a data-
base search (http://utrdb.ba.itb.cnr.it; Additional file 4:
Table S3). Interestingly, and in line with what was re-
cently reported for Staufen targets [18, 30], the average
length of the 5′-UTR of PCBP1 mRNA targets was sig-
nificantly larger than that in the mouse 5′UTRome
(258 bases for PCBP1 targets versus 160 bases for the
mouse 5′UTRome, Wilcoxon rank sum test p ≤ 0,0001;
Fig. 5a). In addition, our data showed an enrichment of
mRNA targets bound by PCBP1 with long 3′UTRs
when compared to the average length of the mouse 3′-
UTR (2,881 bases for PCBP1 targets versus 607 bases
for the mouse 3′UTRome, Wilcoxon rank sum test p ≤
0,001; Fig. 5b). This observation was not seen for the
less enriched transcripts, suggesting that PCBP1 specif-
ically binds to transcripts that have larger UTRs.
We next investigated whether PCBP1 preferentially
binds to specific regions in the larger appreciated UTRs.
We therefore selected the most stringent set of targets,
which was used for the MEME prediction software
(http://meme-suite.org). We found that PCBP1 targets
were highly enriched with a specific poly(C) stretch
(CTCCTCCTCCTCC), pointing to the presence of an
RBP binding sequence (Fig. 5c). The location of the
poly(C) stretch was spread among the entire sequence of
the analysed targets but with a strong enrichment in the
3′- and 5′-UTR. Motif frequency calculations were per-
formed on the sequences extracted (for exons, 5′UTRs,
Fig. 4 Identification and validation of PCBP1 mRNA targets in mouse brain. a Overview of the biochemical procedure to isolate endogenous
PCBP1 and identify its mRNA targets. Normal goat IgG was taken along as a negative control. RNA immunoprecipitation experiments were
performed in triplo, with three different C57Bl/6 mouse brains, in order to rule out biological variation. b Data originating from RNA sequencing
were normalized to the expression level of genes identified in the total brain lysates and to the negative control, IgG. The 4th quartile (top 25%)
of the identified genes was selected for the validation of the performed data analysis. c Ten top and bottom genes of the 4th quartile selected
from the total pool of identified mRNA targets were validated by RNA immunoprecipitation and RT-qPCR, showing the same trend in expression
levels as seen in the RIP sequencing data. Data were normalized by subtracting the input values from the IP and IgG values. Afterwards these
values were corrected for the amplification efficiencies (AE) of the selected genes; AE^[−(IP-input)] and AE^[−(IgG-input)]. Normalized and
corrected IP values are shown in the graph. Multiple t-test with Holm-Sidak as a correction for multiple comparisons was used to test for the
enrichment targets in the IP versus IgG. d Correlation of identified mRNA targets obtained by RNA sequencing versus RT-qPCR. Data values
originating from RIP sequencing and RIP followed by RT-qPCR were normalized to their input values (IP/Input). Each point represents an
individual mRNA, which was quantified using both methods. PCC = Pearson’s correlation coefficient. e Overview of the number of identified
mRNA targets ≥ 2-fold (PCBP1/Input). Note that the fold enrichment values in the graph are presented in log2 scale while the values discussed
in the text are in linear scale. f Selected GO term enrichments observed for PCBP1-associated mRNAs. RNAs enriched ≥ 2-fold (PCBP1/Input)
were used
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Fig. 5 PCBP1 mRNA targets have larger UTRs and share a common recognition sequence. a The average length of the 5′UTRs present in the
top 50 high and low enriched genes was compared to the average length of the mouse 5′UTRome. Wilcoxon rank sum test, p ≤ 0,001. The
same analysis was performed in (b) with the 3′UTR present in the top 50 genes of high and low enriched genes. Wilcoxon rank sum test; p≤ 0,001.
c PCBP1 mRNA targets share a common recognition sequence that is rich in poly(C) repeat stretches. This RNA motif was identified by
subjecting the most stringent set of PCBP1 targets, above ≥ 2-fold, to MEME analysis. d Table with statistics showing the enrichment of the
RNA motif in values
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This was done for two group of genes, representing the
‘enriched set’ and the ‘general set’. From the total of 1,252
differentially expressed genes (≥2-fold enrichment), 1,060
genes (4,524 transcripts) had complete data and the motif
frequencies in exons, 5′UTR, 3′UTR and introns were
calculated (Fig. 5d; table ‘Enriched set’). The second set
contained all the remaining 51,224 transcripts in 16,381
genes (Fig. 5d; table ‘General set’). We generated 100 ran-
dom sets of 4,524 genes from the ‘General set’. The distri-
bution of each random set was compared with the
distribution of the ‘Enriched set’ set using signed two-sam-
ple Kolmogorov-Smirnov test, for exons, 5′UTRs, 3′UTRs
and introns, respectively. The frequencies of the motif in
the ‘Enriched set’ were systematically greater than in the
random sets for all features, with the exception of 3 com-
parisons in the motif frequencies in 5’UTRs, where the
Benjamini-Hochberg corrected pvalue did not reach sig-
nificance level of 0,05. The enrichment of the motif in the
differentially expressed transcripts for all features was un-
equivocally supported by the statistical test (average of ad-
justed pvalue for 100 comparisons; in exons < 7,41 × 10
−10, in 5′UTR < 1,21 × 10−28, in 3′UTR < 1,64 × 10−16 and
in introns < 0,003; Fig. 5d). These data indicate that the
identified motif of PCBP1 is mainly present in the 5′ and
3′UTR of its target genes and therefore supports for an
important role in translational control and mRNA
stabilisation.
PCBP1 targets known neuropathy genes
To date more than 80 disease-associated genes have
been identified for Inherited Peripheral Neuropathies(IPN) including CMT and closely related diseases [49].
The constant discovery of novel genes and mutations
being the cause of this neurological disease suggests a
pleiotropic repertoire of proteins being affected and
causing a similar phenotype. Therefore we looked at the
presence of these known disease-associated genes in our
dataset of genes identified through RNA sequencing (≥2
fold). Interestingly, we saw an overlap between the two
datasets for six genes (Inf2, Sox10, Wnk1, Med25, Kif1a
and Bscl2), where the latter one was specifically causing
a pure dHMN phenotype. These six mRNAs were vali-
dated by RT-qPCR after RNA immunoprecipitation of
PCBP1 on adult mouse brain samples, and were found
to be significantly associated with PCBP1 (Fig. 6a).
Hereditary Spastic Paraplegias (HSPs) are clinically
and genetically heterogeneous disorders with a progres-
sive weakness and spasticity of the lower limbs. Similar
to CMT2/dHMN, the major neuropathological feature
of HSP is axonal degeneration that is maximal in the ter-
minal portions of the longest descending and ascending
neurons [28, 48]. Therefore, we also aimed looking for
the presence of genes known to be associated with HSP
in our dataset (≥2 fold). This search resulted in the iden-
tification of five overlapping genes (Fa2h, Slc12a6, Kif5a,
Kif1a and Bscl2), where the latter two were previously
reported as CMT2/dHMN causing genes [42, 52]. All
the five mentioned genes were detected significantly by
RT-qPCR (Fig. 6b).
To further study the consequences of the increased
interaction between HSPB1-P182L and PCBP1, we in-
vestigated the protein expression level of some PCBP1
targets in mouse NSC-34 motorneuron-like cell lines
Fig. 6 PCBP1 controls the expression of known neuropathy genes. a Venn diagram showing the overlap between genes identified through RIP
sequencing (≥2 fold) and known IPN and dHMN genes. Overlapping genes were confirmed by RNA immunoprecipitation of PCBP1 followed by
RT-qPCR on total mouse brain. Raw Ct values originating from mRNA targets when PCBP1 was pulled down were corrected for the pull down of
IgG and normalized for the Ct values in the total lysate used for the pull down experiment. These obtained values are shown as input percentage
values. b The same approach was done for an additional dataset with all known genes causing HSP. c Co-immunoprecipitation was performed
on NSC-34 cells stably transduced with HSPB1 wild type and mutants. Pull-down was directed against endogenous PCBP1 and the presence of
exogenous HSPB1 was investigated. d The expression level of a selection of identified PCBP1 targets was checked in stably transduced NSC-34 cell
lines by western blot and by RT-qPCR (e). Values are shown as mean with SD as error bar. Multiple t-test with Holm-Sidak as a correction for
multiple comparisons was used as statistical test
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confirmed the increased interaction, seen in patient-derived
lymphoblasts, by performing a co-immunoprecipitation
for PCBP1 on stable NSC-34 cell lines (Fig. 6c). Because
of antibody restrictions we were limited to Mfn2, Atxn1
and Kif5 to investigate their protein expression levels by
western blot. These three genes were identified as
PCBP1 mRNA targets and validated by RIP-qPCR (data
not shown). Interestingly, an increased protein expres-
sion for these genes was observed in cells carrying the
P182L mutation (Fig. 6d), which was not seen at the
mRNA level (Fig. 6e). This increased protein expression
might be a direct consequence of the increased inter-
action between the P182L mutant and PCBP1 leading to
a loss of translational repression.
Discussion
This study reports the poly(C)binding protein 1 (PCBP1)
as a novel binding partner for HSPB1, which forms an
increased interaction with mutant HSPB1-P182L causing
dHMN. We identified this novel interaction by perform-
ing a tandem affinity purification experiment coupled to
mass spectrometry. The availability of patient-derived
material enabled us to confirm our findings and to fur-
ther study the biochemical consequences of this inter-
action. In basal conditions we could not detect any
differences in global protein translation, nor was there a
difference seen in the distribution of HSPB1 and PCBP1
in the different fractions after the separation of poly-
somes and ribosomal subunits by sucrose gradient cen-
trifugation. These data suggest that the identified
interaction between mutant P182L and PCBP1 leads to
subtle effects that are not noticeable in white blood cells
having a lower complexity than neurons. A more specific
approach was chosen to test for the direct consequences
on the function of PCBP1. A luciferase-based transcrip-
tional repression assay showed that PCBP1 gives
approximately 20% less translational repression when
HSPB1-P182L is present. In order to investigate the
possible outcomes of this effect on the mRNA targets of
PCBP1, RNA immunoprecipitation coupled to RNA se-
quencing was performed. Total mouse brain was used
because of the limited amount of starting material in
sciatic nerve and spinal cord. In total 2,320 mRNA tar-
gets (above 2-fold) were identified, all showing a signifi-
cant larger 5′ and 3′UTR when compared to the average
UTR length. Such an enrichment for larger UTRs has
also been reported for Stau2 mRNA targets, which is an
RNA binding protein directing local protein translation
at neuronal synapses. These larger UTRs were enriched
for primary and secondary structures important for the
binding of Stau2 [18]. Indeed, an RNA recognition motif
(CTCCTCCTCCTCC) was highly enriched in the 5′ and
3′UTR of PCBP1 mRNA targets, but to a lesser extentin exons and introns. Defining a conclusive RNA recog-
nition motif for PCBP1 has been found difficult as many
reports have identified different kinds of motifs [51, 55].
Interestingly, all the reported motifs for PCBP1 are
highly enriched for cytosine. It has been shown before
that RNA structures composed out of polycytosines are
more prone to form hairpin loops [35]. Most likely there
is a commonality in the secondary structures formed by
the multiple identified PCBP1 recognition motifs. It is
therefore suggestive that the recognition of mRNA by
PCBP1, and RNA binding proteins in general, is largely
mediated by the secondary structure of the mRNA rather
than its primary structure. Besides the clear presence of
neuronal transcripts seen among the mRNA targets con-
taining PCBP1 recognition motifs, we identified known
genes associated with hereditary peripheral neuropathies
and hereditary spastic paraplegias. Although our approach
to identify PCBP1 mRNA targets started from mouse
brain and not from peripheral nerve tissue material, we
were able to identify genes that showed an increased pro-
tein expression level in mouse motor neuronal cells carry-
ing the HSPB1-P182L mutation. This change in protein
expression hints to a direct consequence of the increased
interaction between mutant HSPB1 and PCBP1. Our
approach suggests that whole brain tissue material can be
used for explorative experiments, like RIP sequencing,
when studying RNA binding proteins involved in motor
neuron diseases. Similar results where obtained for TDP-
43 mRNA targets that were identified using cortical neu-
rons that showed an altered expression profile in motor
neurons when TDP-43 was mutated [45].
The regulation of PCBP1 has recently been found to
be of crucial importance in turning solid tumor cells into
metastatic cells. Altering the expression profile of spe-
cific mRNA targets inhibits the process of metastasis
[22, 23, 47]. Similar to the control of mRNAs responsible
for the transition of cancer cells, it has been shown that
incorrect processing, delivery and regulation of mRNAs
can be the cause of human neurological diseases [53].
Looking at the strong potential of PCBP1 to control the
fate of many mRNAs, it is not surprising that it also con-
trols transcripts important for neuronal processes and
consequently known neuropathy genes. This study identi-
fied a set of ubiquitously expressed genes that are con-
trolled by PCBP1 and contain diverse neuron specific
functions, going from axonal transport to the assistance of
neuronal myelin formation. Conditional knock-out studies
in mice of some of the identified genes (Kif1a, Kif5a and
Slc12a6) all lead to the development of neurodegenera-
tion, often associated with the loss of motor and sensory
neurons [12, 54, 56]. Not all identified genes lead to
neuropathy phenotypes caused by a reduced expression
or loss of protein function. More specifically, mutations
reported in Bscl2 clearly affect N-glycosylation of the
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ing its localization in the endoplasmatic reticulum [52].
Mutations found in Inf2 can result both in a loss or
gain of function as the net result of the mutations are
an increase in filamentous actin. This increase can be
caused by an increase in polymerization activity or a
decrease in the depolymerization activity of mutant
Inf2 [34]. Interestingly, some of the identified targets
(Kif5, Atxn1 and Mfn2) of PCBP1 clearly show a loss of
translational repression in motorneuron-like cells car-
rying the HSPB1-P182L mutation, as shown by their
increase in protein expression. This indicates that the
effect of the HSPB1 mutation on the targets of PCBP1
has direct consequences on motorneuron-like cells.
Nevertheless, precautions have to be made when link-
ing PCBP1 to the expression levels of the identified
neuropathy genes. Besides its strong role in transla-
tional control, which could be enhancing or repressive,
the role of PCBP1 in the transport and stability of
mRNA has to be evaluated as well.
It remains to be determined how the C-terminal P182L
mutation in HSPB1 can affect the binding strength to
other proteins. So far no studies that detail the molecu-
lar structure of human HSPB1 were reported, and thus
the function of its C-terminal extension remains unclear.
In contrast to the N-terminal and the α-crystallin
domain, the C-terminal extension of HSPB1 displays a
large variability in length, sequence conservation and
structure [9]. Despite the low conservation among spe-
cies, the C-terminal extension contains a well-conserved
IXI/V motif that interacts with regions located on neigh-
boring monomers [38]. It is most likely that this motif
mediates for a large part the crucial binding properties
of the C-terminal extension to other monomers when
forming oligomeric structures and to other interacting
proteins. The P182L/S mutations reported so far [14, 27]
are located in the middle of this conserved IXI/V motif
and lead to a dramatic changes in the oligomeric struc-
ture of HSPB1 [9]. The T180I and R188W are two other
mutations that are located in the C-terminal extension
of HSPB1 [6, 32]. Interestingly, the T180I mutation is lo-
cated on the border of the conserved tripeptide IXI/V
motif and consequently leads to the creation of a group
of three consecutive isoleucine residues. Similarly, the
R188W mutation leads to a structural change of the C-
terminal extension by introducing a bulky aromatic
amino acid. Because of the extreme flexible and unstruc-
tured nature of the C-terminal extension it is possible
that altering the organization of amino acids creates
disturbances in the protein binding capabilities of this
molecular chaperone. Besides a prominent need for
flexibility and structure variability, the C-terminal exten-
sion of HSPB1 is also characterized by a high degree of
polar residues. Interestingly, this extension is typicallypointing to the outside when oligomers are being cre-
ated [8]. By doing so, it counteracts the hydrophobicity
of the created oligomer and keeps it soluble by interact-
ing with the polar environment [36]. Therefore, it is of
utmost importance that the C-terminal extension re-
mains polar to maintain environmental interactions.
Interestingly, it has been shown in Xenopus laevis that
the chaperone activity of Hsp30C is drastically impaired
when the polarity of its C-terminal extensions is re-
duced [15]. This highlights the importance of the polar
residues in the C-terminus of sHSPs and probably also
of HSPB1. Interestingly, all reported mutations in the
C-terminal extension of HSPB1 (T180I, P182L/S and
R188W) results in the drastic change from a polar, or
positively charged amino acid, to a hydrophobic amino
acid. It is suggestive that this reduction in polarity
causes the HSPB1 oligomer to make less contact with
solvents in its environment, making it less soluble. This
reduced solubility can consequently increase the affinity
for other binding proteins. The decrease in solubility of
HSPB1-P182L, together with an alteration of the con-
served IXI/V motif probably creates a mutant protein
that affects its binding strength to other proteins, such
as our identified increased interaction with PCBP1.
Conclusions
We report a novel interaction between mutant HSPB1-
P182L and the RNA binding protein PCBP1, leading to a
reduction in its translational repression activity. Identify-
ing PCBP1 mRNA targets revealed a marked prevalence
for an RNA recognition motif, preferably seen in their 5′
and 3′UTRs. Among many neuronal transcripts we iden-
tified known genes associated with hereditary peripheral
neuropathies and hereditary spastic paraplegias. We
hypothesize that mutant HSPB1 can mediate translational
repression by forming an interaction with PCBP1 leading
to an alteration in the expression levels of genes import-
ant to cause peripheral neuropathies. These findings
further support a role for mutant HSPB1 in neurode-
generative diseases.Additional files
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